Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

NCT07559864 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

GIST - Gastrointestinal Stromal Tumor
KIT Gene Mutation

Interventions

DRUG: physician-selected treatment
DRUG: Regorafenib + Envafolimab

Sponsor

Jian Li